浩欧博（SH 688656，收盘价：120.29元）8月4日晚间发布公告称，江苏浩欧博生物医药股份有限公司 全资子公司湖南浩欧博生物医药有限公司于近日获得湖南省药品监督管理局核准签发的3项医疗器械注 册证。包括"葎草（W22）过敏原特异性IgE抗体检测试剂盒"等产品。 2024年1至12月份，浩欧博的营业收入构成为：医疗器械占比97.39%，其他业务占比2.61%。 （文章来源：每日经济新闻） ...

Core Viewpoint - The company, Haobio, announced that its wholly-owned subsidiary, Hunan Haobio Pharmaceutical Co., Ltd., has received approval from the Hunan Provincial Drug Administration for three medical device registration certificates, enhancing its competitive position in the market [1] Group 1 - The approved medical devices include specific IgE antibody test kits for allergens: W22, food mixed FX5 (magnetic chemiluminescence method), and inhalant mixed SX (magnetic chemiluminescence method) [1] - The acquisition of these registration certificates will enrich the company's chemiluminescence platform testing menu, potentially improving its market competitiveness [1] - The actual sales performance will depend on future market expansion efforts, and the impact on the company's future performance remains unpredictable [1]